Pharma plants are awash in data. There are myriad sources: MES for execution status, LIMS (QC results), process historians (equipment conditions), QMS (quality/deviations) to name just a few, but release decisions still stall when those sources disagree or lack an owner. To deal with the chaos, eschbach’s visual factory centers daily work on SQDCP boards…
In 2023, Roche and Novartis led the pack in drug pipeline scale
When reviewing R&D spending trends for 2023, Merck & Co. is a clear outlier given its decision to count its $10.3 billion Prometheus acquisition as an R&D charge. In all, the company committed more than half of its revenue to R&D. But Swiss giants Roche and Novartis remain frontrunners in terms of their pipeline of…
Accelerating biologics R&D with unified software and data flows
Biologics are changing the way we treat disease, affecting where companies invest and, most importantly, impacting patients’ lives. Last year, nearly half of the 37 new drugs approved by FDA’s Center for Drug Evaluation and Research (CDER) were biologics. Its partner agency — the agency’s Center for Biologics Evaluation and Research (CBER)—approved a dozen additional…